Botanix Pharmaceuticals (ASX:BOT) is on track to launch its patient experience program for underarm sweating prescription, Sofdra, in the fourth quarter of the 2024 calendar year, according to a Monday filing with the Australian bourse.
The program intends to introduce Sofdra to its first commercial users for initial feedback before being rolled out to larger volumes of patients in the first quarter of 2025.
The clinical dermatology company added that it is on pace to generate first prescriptions from the sales in the coming months, followed by first refills.
Botanix's shares were up 6% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.